Conferences - Results from #9680

ASCO 2017: Integrated biomarker analysis for 412 renal cell cancer patients treated on the phase 3 COMPARZ trial June 4, 2017

ASCO 2017: Association of on-treatment plasma HGF levels with overall survival in patients with advanced renal cell carcinoma treated with interferon alpha +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance) June 4, 2017

ASCO 2017: Impact of perioperative chemotherapy and radiation for locally advanced penile squamous cell carcinoma June 4, 2017

ASCO 2017: Incidence of T3a upstaging and survival after partial nephrectomy: Size-stratified rates and implications for prognosis June 4, 2017

ASCO 2017: Nivolumab treatment for patients with non-clear cell renal cell carcinoma: A multicenter retrospective analysis June 4, 2017

ASCO 2017: Impact of geographic region on overall survival in patients with metastatic renal cell carcinoma: Results from a pooled clinical trials database June 4, 2017

ASCO 2017: Effects of pazopanib and sunitinib dose modification on safety and efficacy in patients with metastatic renal cell carcinoma from COMPARZ June 4, 2017

ASCO 2017: Long-term response and time to response to pazopanib and sunitinib in metastatic renal cell carcinoma: COMPARZ subanalysis June 4, 2017

ASCO 2017: Penile Cancer: Current Evidence and Controversies June 4, 2017

ASCO 2017: Safety and usefulness of patient-centered shared survivorship care after chemotherapy for testicular cancer June 4, 2017

ASCO 2017: FDG PET scan (PET) positive residual lesions after chemotherapy (chemo) for metastatic seminoma: Results of an International Global Germ Cell Cancer Group (G3) registry June 4, 2017

ASCO 2017: Management Strategies for Nonurothelial Bladder Cancer June 4, 2017

ASCO 2017: Phase II trial of pembrolizumab in patients (pts) with incurable platinum refractory germ cell tumors (GCT) June 4, 2017

ASCO 2017: Infusional gemcitabine + docetaxel/melphalan/carboplatin (GemDMC) ± bevacizumab (BEV) as an effective high-dose chemotherapy (HDC) regimen for refractory of poor-risk relapsed germ-cell tumors (GCT) June 4, 2017

ASCO 2017: Multiregion sequencing of penile cancer to reveal distinct patterns of heterogeneous actionable mutations June 4, 2017

ASCO 2017: Comprehensive genomic profiling (CGP) of advanced papillary renal cell carcinoma (PRCC) to reveal distinctions from TCGA dataset June 4, 2017

ASCO 2017: Checkpoint inhibitors in metastatic renal cell carcinoma patients including elderly subgroups: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) June 4, 2017

ASCO 2017: Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC) June 4, 2017

ASCO 2017: Safety and efficacy of nivolumab for metastatic renal cell carcinoma (mRCC): Real world data from an Italian expanded access program (EAP) June 4, 2017

ASCO 2017: Phase II study of pazopanib in patients with von Hippel-Lindau disease June 4, 2017

Page 485 of 616